Moderna’s impressive portfolio leveraging cutting-edge innovation propels it as a noteworthy competitor to industry giants like Pfizer, Sanofi, AstraZeneca, and GSK.
From their groundbreaking COVID-19 vaccine to their recent RSV vaccine approval and outstanding data for the COVID-19+Flu combination vaccine, Moderna is setting new standards and pushing the boundaries of what’s possible in medicine.
‘Moderna’izing Health
Agility, innovation and creativity fuels Moderna’s strategic choices and makes us all wonder how they will leverage their competitive advantages in vaccines and beyond.
To learn more about Moderna’s vaccines portfolio, strategy and upcoming milestones, read the full report below.
Related Insights & Outlooks
Migraine Key Catalysts for 2023
Atacana Group
•
June 1, 2023
While there is no cure for migraine, pharmaceutical companies continue to innovate to provide treatment options for patients suffering from migraine.
Novel and Emerging Treatments in Spinal Muscular Atrophy
Atacana Group
•
June 1, 2023
Marketed products are being evaluated for age expansion, dose increase, and in previously treated SMA patients
Antiviral Vaccines 2024 & 2025 Catalysts Report
Atacana Group
•
April 19, 2024
The Leading companies in the Antiviral Vaccine market, such as Pfizer, Moderna, GSK, and AstraZeneca are anticipating pivotal advancements, including regulatory milestones, clinical trial updates, and strategic product launches.
.avif)